Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Extramedullary Plasmacytoma Treatment & Management

  • Author: Suzanne R Fanning, DO; Chief Editor: Emmanuel C Besa, MD  more...
 
Updated: Dec 01, 2015
 

Medical Care

See the list below:

  • Solitary bone plasmacytoma (SBP)
    • Local radiotherapy is the treatment of choice.[4, 5, 16, 29] Treatment fields should be designed to encompass all disease observed on MRI and should include a margin of healthy tissue (at least 2 cm). For spinal lesions, the margins should include at least 1 uninvolved vertebra.
    • Local control is achieved in 88-100% of patients. Virtually all patients have major symptom relief.[16] and a local tumor recurrence rate of approximately 10%.
    • Most centers use approximately 40 Gy for spinal lesions and 45 Gy for other bone lesions. For lesions larger than 5 cm, 50 Gy should be considered.
    • No dose-response relationship between radiation dose and disappearance of monoclonal protein was noted in a series of patients with solitary bone plasmacytoma as reported by Liebross et al.[29]
    • Monoclonal protein is markedly reduced after radiotherapy in the majority of patients, but protein disappearance is observed in only 20-50% of patients.[17]
    • Surgery is contraindicated in the absence of structural instability or neurologic compromise.[15]
    • Chemotherapy may be considered for patients not responding to radiation therapy. Regimens useful in multiple myeloma can be considered.[15]
    • No role exists for adjuvant chemotherapy in solitary bone plasmacytoma (SBP).
  • Extramedullary plasmacytoma (EMP)
    • Based on the documented radiation sensitivity of plasma cell tumors, the accepted treatment is radiotherapy.
    • When a lesion can be completely resected, surgery provides the same results as radiotherapy.
    • Combined therapy (surgery and radiotherapy) is an accepted treatment depending on the resectability of the lesion.[4, 6, 16, 17, 18] In fact, combination treatment may provide the best results.[17]
    • The optimal dose for local control is 40-50 Gy (depending on tumor size) delivered over 4-6 weeks.[16, 17, 18]
    • Because of the high rate of lymph node involvement, these areas should be included in the radiation field.[16]
    • Adjuvant radiotherapy should be recommended to patients with positive surgical margins.
    • Chemotherapy may be considered for patients with refractory or relapsed disease. Regimens used for multiple myeloma can be considered.[15]
    • Adjuvant chemotherapy may be considered for patients with tumors larger than 5 cm, as well as those with high-grade histology.
Next

Surgical Care

See the list below:

  • Although surgical resection is not advised for the treatment of solitary bone plasmacytoma (SBP), spine instrumentation or another procedure is sometimes necessary to try to reestablish the normal architecture of the spine or other bone affected.
  • If possible, a complete resection of the lesion, including lymph node dissection, should be attempted for soft-tissue plasmacytomas.
Previous
Next

Consultations

See the list below:

  • Orthopedic evaluation is recommended for patients with solitary bone plasmacytoma (SBP) because lesions may cause spinal cord compression syndrome or impending fractures. Therapeutic procedures, such as kyphoplasty, can be implemented in order to restore vertebral structure.
  • An ear, nose, and throat evaluation is recommended for patients with extramedullary plasmacytoma (EMP) of the head and neck to precisely localize the lesion, obtain an adequate biopsy (including lymph nodes), and plan possible resection.
Previous
 
 
Contributor Information and Disclosures
Author

Suzanne R Fanning, DO Fellow, Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, 2004-2007 Director, Hematology, Greenville Memorial Health System, Greenville, SCMedical Oncologist/Hematologist/Transplant Pysician, Cancer Centers of the Carolinas

Suzanne R Fanning, DO is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Hematology, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology

Disclosure: Received consulting fee from Millenium Pharmaceuticals for review panel membership; Received consulting fee from Celgene Pharmaceuticals for review panel membership.

Coauthor(s)

Mohamad A Hussein, MD Clinical Director, Malignant Hematology, Moffitt Cancer Center

Mohamad A Hussein, MD is a member of the following medical societies: American Association of Blood Banks, American College of Physicians, American Medical Association, American Society of Hematology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Paul Schick, MD Emeritus Professor, Department of Internal Medicine, Jefferson Medical College of Thomas Jefferson University; Research Professor, Department of Internal Medicine, Drexel University College of Medicine; Adjunct Professor of Medicine, Lankenau Hospital

Paul Schick, MD is a member of the following medical societies: American College of Physicians, American Society of Hematology

Disclosure: Nothing to disclose.

Acknowledgements

Wendy Hu, MD Consulting Staff, Department of Hematology/Oncology and Bone Marrow Transplantation, Huntington Memorial Medical Center

Wendy Hu, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Blood and Marrow Transplantation, American Society of Hematology, and Physicians for Social Responsibility

Disclosure: Nothing to disclose.

Fernando Perez-Zincer, MD Senior Fellow, Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation Cancer Center

Disclosure: Nothing to disclose.

References
  1. Bataille R, Sany J. Solitary myeloma: clinical and prognostic features of a review of 114 cases. Cancer. 1981 Aug 1. 48(3):845-51. [Medline].

  2. Corwin J, Lindberg RD. Solitary plasmacytoma of bone vs. extramedullary plasmacytoma and their relationship to multiple myeloma. Cancer. 1979 Mar. 43(3):1007-13. [Medline].

  3. McLain RF, Weinstein JN. Solitary plasmacytomas of the spine: a review of 84 cases. J Spinal Disord. 1989 Jun. 2(2):69-74. [Medline].

  4. Dimopoulos MA, Kiamouris C, Moulopoulos LA. Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am. 1999 Dec. 13(6):1249-57. [Medline].

  5. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000 Sep 15. 96(6):2037-44. [Medline]. [Full Text].

  6. Galieni P, Cavo M, Pulsoni A, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica. 2000 Jan. 85(1):47-51. [Medline]. [Full Text].

  7. Sabir H, Kumbhare S, Parate A, Gupta S, Tale R. A 65-year old female with synchronous HIV and Extramedullary Plasmacytoma of Maxillary sinus. Gulf J Oncolog. 2015 Sep. 1 (19):18-23. [Medline].

  8. Zhang L, Zhang X, Zhang R, Fan W. 18F-FDG PET/CT Metabolic Activity in a Patient With Solitary Extramedullary Plasmacytoma of the Lung. Clin Nucl Med. 2015 Oct 12. [Medline].

  9. Wiltshaw E. The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine (Baltimore). 1976 May. 55(3):217-38. [Medline].

  10. Frizzera G. Castleman's disease and related disorders. Semin Diagn Pathol. 1988 Nov. 5(4):346-64. [Medline].

  11. Hussong JW, Perkins SL, Schnitzer B, Hargreaves H, Frizzera G. Extramedullary plasmacytoma. A form of marginal zone cell lymphoma?. Am J Clin Pathol. 1999 Jan. 111(1):111-6. [Medline].

  12. Aalto Y, Nordling S, Kivioja AH, et al. Among numerous DNA copy number changes, losses of chromosome 13 are highly recurrent in plasmacytoma. Genes Chromosomes Cancer. 1999 Jun. 25(2):104-7. [Medline].

  13. Low SF, Mohd Tap NH, Kew TY, Ngiu CS, Sridharan R. Non Secretory Multiple Myeloma With Extensive Extramedullary Plasmacytoma: A Diagnostic Dilemma. Iran J Radiol. 2015 Jul. 12 (3):e11760. [Medline].

  14. Pasqualetti P, Festuccia V, Collacciani A, Casale R. The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases. Acta Haematol. 1997. 97(3):174-9. [Medline].

  15. Soutar R, Lucraft H, Jackson G, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Clin Oncol (R Coll Radiol). 2004 Sep. 16(6):405-13. [Medline].

  16. Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. Oncology (Williston Park). 2000 Jan. 14(1):101-8, 111; discussion 111-2, 115. [Medline].

  17. Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999 Jun 1. 85(11):2305-14. [Medline]. [Full Text].

  18. Liebross RH, Ha CS, Cox JD, et al. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999 Sep. 52(3):245-9. [Medline].

  19. Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am. 1997 Feb. 11(1):71-87. [Medline].

  20. Krishnasamy G, Dhanasekar G. Extramedullary plasmacytoma of postnasal space. Kulak Burun Bogaz Ihtis Derg. 2013 May-Jun. 23(3):183-6. [Medline].

  21. Belic B, Mitrovic S, Arsenijevic S, Erdevicki L, Stojanovic J, Stojanovic S, et al. Nasal septum extramedullary plasmacytoma. Vojnosanit Pregl. 2013 Feb. 70(2):221-4. [Medline].

  22. Erdogan BA, Sekercan O, Dursun N, Tatar G, Bora F. Extramedullary plasmacytoma of maxillary sinus. J Craniofac Surg. 2013 Jan. 24(1):e85-7. [Medline].

  23. Burt M, Karpeh M, Ukoha O, et al. Medical tumors of the chest wall. Solitary plasmacytoma and Ewing's sarcoma. J Thorac Cardiovasc Surg. 1993 Jan. 105(1):89-96. [Medline].

  24. Read D, Warlow C. Peripheral neuropathy and solitary plasmacytoma. J Neurol Neurosurg Psychiatry. 1978 Feb. 41(2):177-84. [Medline]. [Full Text].

  25. Schindler OS, Briggs TW, Gillies SA. Bilateral demyelinating neuropathy in a solitary lytic and sclerotic myeloma of the proximal humerus: a case report. Int Orthop. 1997. 21(1):59-61. [Medline].

  26. Iwashita H, Ohnishi A, Asada M, Kanazawa Y, Kuroiwa Y. Polyneuropathy, skin hyperpigmentation, edema, and hypertrichosis in localized osteosclerotic myeloma. Neurology. 1977 Jul. 27(7):675-81. [Medline].

  27. Puliga G, Olla L, Bellisano G, Di Naro N, Ganau M, Lai ML, et al. Solitary extramedullary plasmacytoma of the thyroid gland associated with multinodular goiter: case report and review of the literature. Pathologica. 2011 Jun. 103(3):61-3. [Medline].

  28. Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol. 1983 Apr. 1(4):255-62. [Medline].

  29. Liebross RH, Ha CS, Cox JD, et al. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys. 1998 Jul 15. 41(5):1063-7. [Medline].

  30. Brinch L, Hannisdal E, Abrahamsen AF, Kvaløy S, Langholm R. Extramedullary plasmacytomas and solitary plasma cell tumours of bone. Eur J Haematol. 1990 Feb. 44(2):132-5. [Medline].

  31. Bolek TW, Marcus RB, Mendenhall NP. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys. 1996 Sep 1. 36(2):329-33. [Medline].

  32. Jackson A, Scarffe JH. Prognostic significance of osteopenia and immunoparesis at presentation in patients with solitary myeloma of bone. Eur J Cancer. 1990 Mar. 26(3):363-71. [Medline].

  33. Galieni P, Cavo M, Avvisati G, et al. Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities?. Ann Oncol. 1995 Sep. 6(7):687-91. [Medline].

  34. Holland J, Trenkner DA, Wasserman TH, Fineberg B. Plasmacytoma. Treatment results and conversion to myeloma. Cancer. 1992 Mar 15. 69(6):1513-7. [Medline].

  35. Frassica DA, Frassica FJ, Schray MF, Sim FH, Kyle RA. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1989 Jan. 16(1):43-8. [Medline].

  36. Huvos AG, ed. Multiple myeloma including solitary osseous myeloma. Bone Tumors: Diagnosis, Treatment, and Prognosis. Philadelphia, Pa: WB Saunders Co; 1992. 653-67.

  37. Miralles GD, O'Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med. 1992 Dec 31. 327(27):1919-23. [Medline].

  38. Moulopoulos LA, Dimopoulos MA, Weber D, et al. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol. 1993 Jul. 11(7):1311-5. [Medline].

  39. Ooi GC, Chim JC, Au WY, Khong PL. Radiologic manifestations of primary solitary extramedullary and multiple solitary plasmacytomas. AJR Am J Roentgenol. 2006 Mar. 186(3):821-7. [Medline]. [Full Text].

  40. Yu SC, Chen SU, Lu W, Liu TY, Lin CW. Expression of CD19 and lack of miR-223 distinguish extramedullary plasmacytoma from multiple myeloma. Histopathology. 2011 May. 58(6):896-905. [Medline].

  41. Susnerwala SS, Shanks JH, Banerjee SS, et al. Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. Br J Cancer. 1997. 75(6):921-7. [Medline].

  42. Wilder RB, Ha CS, Cox JD, et al. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 2002 Mar 1. 94(5):1532-7. [Medline]. [Full Text].

  43. Mendenhall CM, Thar TL, Million RR. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys. 1980 Nov. 6(11):1497-501. [Medline].

  44. Bachar G, Goldstein D, Brown D, et al. Solitary extramedullary plasmacytoma of the head and neck--long-term outcome analysis of 68 cases. Head Neck. 2008 Aug. 30(8):1012-9. [Medline].

  45. Bezwoda WR, Gordon V, Bagg A, Mendelow B. Light chain restriction analysis of bone marrow plasma cells in patients with MGUS or 'solitary' plasmacytoma: diagnostic value and correlation with clinical course. Br J Haematol. 1990 Apr. 74(4):420-3. [Medline].

  46. Bink K, Haralambieva E, Kremer M, et al. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica. 2008 Apr. 93(4):623-6. [Medline]. [Full Text].

  47. Delauche-Cavallier MC, Laredo JD, et al. Solitary plasmacytoma of the spine. Long-term clinical course. Cancer. 1988 Apr 15. 61(8):1707-14. [Medline].

  48. Kumar S, Fonseca R, Dispenzieri A, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood. 2003 Mar 1. 101(5):1715-7. [Medline]. [Full Text].

  49. Mill WB, Griffith R. The role of radiation therapy in the management of plasma cell tumors. Cancer. 1980 Feb 15. 45(4):647-52. [Medline].

  50. Straetmans J, Stokroos R. Extramedullary plasmacytomas in the head and neck region. Eur Arch Otorhinolaryngol. 2008 Feb 26. epub ahead of print. [Medline].

  51. Weber DM. Solitary bone and extramedullary plasmacytoma. Hematology Am Soc Hematol Educ Program. 2005. 373-6. [Medline]. [Full Text].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.